Introduction and Aim: The type I interferon (IFN) system and autoreactive B lymphocytes are activated in lupus and several other rheumatic autoimmune diseases. The main producer of IFN-a is the plasmacytoid dendritic cell (PDC), which can be activated by immune complexes (IC) containing nucleic acid. We have previously described that NK cells have a stimulatory effect on the IFN-a production by PDCs activated by RNA-IC consisting of purified U1 snRNP and SLE-IgG. In the present study we investigate the role of B cells in the regulation of the PDC functions, and especially the type I IFN production. Methods: PDC and B cells were isolated from peripheral blood mononuclear cells using magnetic beads. PDC alone or in cocultures with B cell were stimulated with RNA-IC, herpes simplex virus (HSV) or the CpG containing ODN2216.
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Supernatants from stimulated B cells were collected after 20h and added to some PDC cultures. Produced IFN-a in cell culture supernatants were measured after 20h with an immunoassay. Results: B cells enhance the IFN-a production by PDC, 3 to 15 fold (appr. from 1000 to 8000 U/ml), when stimulated with RNA-IC, HSV or ODN2216, (p<0.001). B cells are more potent to enhance PDC when stimulated with HSV than with RNA-IC and ODN2216 (p¼0.0015 and p¼0.016, respectively) . PDC and B cells form cell aggregates in the stimulated cocultures but not when unstimulated. Supernatants from stimulated B cells enhance the IFN-a production by PDC, but are not as potent as when B cells are cocultivated with PDC. Conclusion: Our findings reveal an important interaction between the innate and adaptive immune system where B cells have the capacity to promote the PDC function and increase the type I IFN response to several different IFN-a inducers. Because B cells are activated by type I IFN, this PDC-B-cell cross-talk may be of fundamental importance in the etiopathogenesis of SLE and contribute both to the observed IFN signature and the autoantibody production in this disease. Objectives: Helios, a member of the Ikaros transcription factor family, was recently introduced as a marker that differentiates thymic-derived natural FoxP3þ regulatory T cells from Helios-FoxP3þ peripherally induced Tregs. In this study we aimed to analyse the levels of circulating Heliosþ natural Tregs in systemic lupus erythematosus (SLE). Methods: Multicolor flow cytometry was performed to analyse the coexpression of Helios, CD45RA, CD31 and Ki-67 in FoxP3þ Tregs from peripheral blood of 20 patients with SLE, 20 age-and sex matched healthy controls (HC), 10 patients after thymectomy for myasthenia gravis and a cohort of aged HC (50-95y). Statistical analyses were performed using a paired t-test. Findings: SLE patients showed significantly higher levels of circulating FoxP3þ Tregs among CD4þ T cells compared to HC (mean 14.5 vs. 7.2%, p¼0.002), with Helios being coexpressed at significantly higher levels in SLE (mean 81.4 vs. 69.0%, p<0.0001). Among CD4þ T cells, levels of Heliosþ FoxP3þ Tregs were significantly higher in SLE compared to HC (mean 12.2% vs. 4.9%, p¼0.001), whereas Helios-FoxP3þ induced Tregs were similar between groups. With respect to Treg subsets, Heliosþ cells were predominantly confined to the FoxP3lo CD45RAþ and FoxP3hi CD45RA-Treg subsets and to a lesser content to FoxP3lo CD45RA-Tregs. Within the naı¨ve CD45RAþ FoxP3lo Treg subset, coexpression levels of CD31 were significantly lower in SLE (p¼0.03) and patients after thymectomy (p¼0.001) compared to HC and Ki-67 stainings revealed significantly higher proliferation rates among these naı¨ve Tregs in SLE (p¼0.04). During ageing, Helios levels are well maintained on CD45RAþ Tregs with levels around 80%, while coexpression levels for CD31 significantly decline (from 90% on cord blood to 15% in a 95y old HC). Conclusion: We are the first to demonstrate that circulating Heliosþ FoxP3þ natural Treg levels are significantly increased in SLE. Decreased coexpression levels for CD31 as well as increased levels for Ki-67 on CD45RAþ Tregs in SLE suggest, that these Tregs do not result from an increased thymic output but rather from peripheral expansion. The factors that drive this proliferation remain elusive and merit further investigations. Patients and Methods: The ability of keratinocytes to produce IFN lambda in response to immunostimulatory nuclear acids was determined in cell culture experiments using epidermal explants and primary human keratinocytes. IFN expression in skin biopsies and IFN lambda serum levels were measured in patients with cutaneous LE, dermatomyositis (DM), lichen planus (LP) and healthy controls by immunohistochemistry and ELISA. The functional impact of IFN lambda on lymphocyte recruitment was proved in cell migration studies. Results: IFN lambda1 and the IFN lambda-receptor are strongly expressed in active skin lesions of patients with CLE, LP and DM. IFN lambda1-serum levels are significantly enhanced in CLE patients and this increase is associated with the extent of skin lesions. Functional analyses revealed that human keratinocytes are able to produce high levels of IFN1 but only low amounts of IFNa/b/g in response to polyIC, suggesting that IFN is a major IFN produced by these cells. IFN1-stimulation induces the expression of several proinflammatory cytokines in keratinocytes, including CXCL9, which drive the recruitment of immune cells and are associated with the formation of CLE skin lesions. Conclusion: Our observations provide several lines of evidence that keratinocyte-derived IFNlambda has a role in the pathophysiology of CLE. First, IFNlambda was strongly expressed in the epidermis of CLE skin lesions.
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Second, enhanced IFNlambda levels could be measured in the serum of patients with active disease. Third, the lesional expression pattern of IFNlambda correlates with that of the IFNlambda-inducible chemokine CXCL9, compatible with the notion that IFNl drives the inflammatory recruitment of immune cells. Based on our in vitro studies with explanted epidermal sheets, cultured keratinocytes, and cell migration analyses, it is highly plausible that the IFNl1 in CLE patients derives from keratinocytes and supports the formation of inflammatory skin lesions. Our results provide first evidence for a role of type III IFNs not only in anti-viral immunity but also in autoimmune diseases of the skin.
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Are neuropsychological impairments in systemic lupus erythematosus independent of psychopathology? Cavaco S 1,2 , Martins da Silva A 11 North Shore-LIJ Health System, Lake Success, New York, USA Introduction: BLISS-76 (NCT00410384) was a 76wk, double-blind, international, Ph3 study of belimumab in seropositive SLE. Aim: Assess belimumab's efficacy/safety in BLISS-76. Methods: 819 patients with SELENA-SLEDAI (SS) 6 received belimumab 1 or 10 mg/kg, vs placebo, plus routine SLE therapy for 76wk. Primary endpoint: wk52 response rate by SRI (SLE Responder Index): improvement in SS (4 points), no new BILAG A and no more than 1 B flare, and no PGA worsening. SRI at wk76 was a secondary endpoint.
Results: Belimumab 10 mg/kg met primary endpoint, with higher wk52 SRI rate vs placebo (43%vs34%; p¼0.017); rate with 1 mg/kg: 41% (p¼0.09). Wk76 rates were not significantly different (39% [p¼0.11], 39% [p¼0.13], 32% with belimumab 1 mg/kg, 10 mg/kg, placebo, respectively). Post-hoc SRI analyses using SS reductions of 5-7 points showed significantly higher response with belimumab 10 mg/kg at wk52þ76.
Between wk24-76, belimumab reduced all flares (10 mg/kg; p<0.05) and severe flares (1 mg/kg; p<0.05).
Fatigue improved in both belimumab groups at wk76 (1 mg/kg; p<0.05). Belimumab was associated with reduction in SLE-specific and short-lived plasma cells, and other B-cell subsets (CD20þ, activated, plasmacytoid). Greater reductions in autoantibody and increases in complement values occurred with belimumab 10 mg/kg vs placebo. AEs were comparable across groups. Serious/severe infusion reactions occurred in 1.5% belimumab 10 mg/kg vs 0.7% placebo patients. Conclusion: Belimumab plus routine therapy significantly reduced SLE disease activity with a safety profile comparable to placebo plus routine therapy. ;T EM ) migrate into the urine during active LN. Aim: The objective of this study was to assess the diagnostic value of urinary T-cells in comparison with traditional markers of active LN. Patients and Methods: Twenty-one, in most cases biopsy proven, active LN patients and 23 patients without active LN were enrolled. In 10 patients with active LN measurements were repeated after at least 6 months. Apart from routine diagnostics (serum creatinine, antidsDNA, complement C3 and C4, urine sediment, proteinuria), the number of effector memory T-cells in the urine during active LN and during remission were determined by flow cytometry. Results: Analysis of the urine during active renal disease showed an increased number of CD4 þ and CD8 þ T-cells in comparison to urine samples obtained during remission. Serial analysis of patients after active renal disease revealed that T-cells almost completely disappeared after follow-up for at least 6 months. This contrasts to other measures such as proteinuria and/or s-creatinine levels, which did not normalise. Conclusion: Enumerating T-cell counts in LN patients was a superior marker of active LN in comparison to traditional markers such as proteinuria and s-creatinine. Urinary T-cells are a promising marker to assess renal activity in LN patients reflecting histo-pathologic injury in particular in those with previous renal involvement.
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Belimumab significantly reduced autoantibodies, normalised low complement, and reduced selected B-cell populations in seropositive SLE patients: BLISS-52/BLISS- Introduction: Two randomised, double-blind, placebo-controlled, phase 3 studies examined safety/efficacy of belimumab in SLE patients. Aim: To assess belimumab's effects on biomarkers, and B-/T-cell populations in BLISS-52 (NCT00424476)/-76 (NCT00410384). Methods: 1684 seropositive SLE patients with SELENA-SLEDAI 6 received belimumab 1 or 10 mg/kg, or placebo, plus routine SLE therapy for 52wk (BLISS-52) or 76wk (BLISS-76). Assessments: immunoglobulin, complement (C), and autoantibodies; B-/T-cell subsets in BLISS-76 only. Results: Belimumab treatment reduced autoantibody titers. More belimumab-than placebo-treated patients converted from seropositive to seronegative for anti-dsDNA, anti-Sm, antiribosomal P, and aCL-IgG antibodies. Belimumab patients had significantly greater C3 and C4 increases, with a dose response evident by wk4. Hypergammaglobulinaemia normalisation occurred in significantly more patients with belimumab. Belimumab significantly reduced circulating B-cell, but not T-cell subsets. Naı¨ve B-cell, short-lived plasma cell, and SLE B-cell subset reductions occurred as early as wk8 with belimumab 10 mg/kg.
Memory B cells increased 100% by wk8 and gradually decreased toward baseline through wk52. A modest expansion of T-cell subsets was observed at wk52. Conclusions: Consistent with its mechanism-ofaction, belimumab produced rapid, significant, and sustained reductions in autoantibodies, normalisation of C3, C4, and hypergammaglobulinaemia, and selective reduction of B-cell and short-lived plasma cell subsets vs placebo. The observed expansion of T cells was modest and potentially secondary to belimumab's effects on B-cell reductions.
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Cyclophosphamide versus azathioprine/methylprednisolone: long-term follow-up of the first dutch lupus nephritis study Arends S , 13 pulses in 2 years) combined with oral prednisone (OP) (CY group; n¼50) or AZA (2 mg/kg/day) combined with intravenous MP (3x3 pulses of 1000 mg) and OP (AZA/MP group; n¼37). After 2 years, therapy was identical in both groups; AZA (2mg/kg/day) combined with OP. After 4 years, it was advised to taper the dosage of both drugs over a year. Results: After a median follow-up of 9.6 years (range 0.1-13.2), 11% of patients reached sustained doubling of serum creatinine (CY: 8%; AZA/MP: 16%), 22% had a renal relapse (CY: 10%; AZA/MP: 38%), 5% reached end-stage renal disease (ESRD; CY: 4%; AZA/MP: 5%), and 13% died (CY: 10%; AZA/MP: 16%). Relapses occurred significantly more often in the AZA/MP group (HR: 4.5, 95% CI: 1.6.-12.4). No significant differences between treatment groups were found in the proportion of patients with sustained doubling of serum creatinine, ESRD, and mortality, or in serum creatinine, proteinuria, and cytotoxic treatment regimens at last follow-up. Conclusion: This open-label randomized controlled trial showed that CY is superior to AZA/MP in the prevention of renal relapses. The proportion of patients with sustained doubling of serum creatinine, ESRD, or mortality was relatively low and comparable between the two treatment groups after 10-year follow-up. Human Genome Sciences, Inc., Rockville, Maryland, USA Introduction: Belimumab efficacy/safety were studied in 1684 seropositive SLE patients in two Ph3 double-blind, randomised, placebo-controlled trials (NCT00424476/NCT00410384). Aim: Assess belimumab efficacy in patients with specific clinical and serological disease activity markers. Methods: Patients with SELENA-SLEDAI6 on routine SLE therapy received belimumab 1 mg/kg, 10 mg/kg, or placebo, plus routine therapy. Primary endpoint (SLE Responder Index [SRI] at week-52) and secondary endpoints (SRI at week-76, flares, fatigue, corticosteroid use) were analyzed post-hoc in patients with baseline low complement and positive anti-dsDNA or on corticosteroids. Results: Mean baseline characteristics were similar across treatment groups.
Conclusion: Belimumab significantly reduced disease activity, flares, and fatigue, and decreased corticosteroid use in SLE patients with more active disease as defined by low complement and positive antidsDNA or on corticosteroids. In the former subset, SRI response rate with belimumab 10 mg/kg remained significantly higher than with placebo through week-76.
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Epratuzumab demonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus (SLE): results from emblem Objective: To present a pooled analysis of the efficacy of rituximab in real-life patients diagnosed with biopsy-proven lupus nephropathy (LN) from European cohorts who were treated with rituximab. Methods: Consecutive patients with severe or refractory LN from tertiary European centres. Epidemiological data, SLEDAI and BILAG scores and renal parameters were evaluated at baseline, 6 and 12 months. Results: 164 patients treated with rituximab were included (145 women and 19 men, with a mean age of 32 years). The mean duration of SLE and LN at the time of rituximab treatment was 8.1 and 5.8 years, respectively.
According to the ISN/RPS classification, renal biopsy showed type III glomerulonephritis in 26 (16%) patients, type IV in 93 (57%), type V in 20 (12%), type II in 6 (4%) and mixed types in 19 (12%). Previous immunosuppressive therapy included cyclophosphamide in 131 patients (80%), mycophenolate in 105 (64%), azathioprine in 98 (60%), methotrexate in 23 (14%) and cyclosporine in 10 (6%). Rituximab was administered in combination with corticosteroids (99%) and immunosuppressive agents (76%) (cyclophosphamide¼58, mycophenolate¼55). At 6-and 12-months, respectively, response rates were 27% and 30% for complete response, 40% and 37% for partial response and 33% for no response. Baseline proteinuria > 3gr/24h predicted a worse response at 6 months (p¼0.015) and 12 months (p<0.001). Baseline eGFR <60ml/min predicted a worse response at 12 months (0.038) but not at six months (p¼0.202). CD19þ depletion was associated with a greater rate of renal response (p¼0.055). Conclusion: Despite the recent negative controlled trials, rituximab is currently used to treat severe refractory autoimmune diseases.
Rituximab may be an effective option for patients with lupus nephritis, especially those refractory to standard treatment or who experience a new flare after intensive immunosuppressive treatment. 11 North Shore-LIJ Health System, Lake Success, New York, USA Introduction: Two randomised, double-blind, placebo-controlled, phase 3 studies examined belimumab's safety and efficacy in seropositive SLE patients. Aim: To assess belimumab's efficacy over 52wks by pooling data from BLISS-52 (NCT00424476)/-76 (NCT00410384). Methods: 1684 patients with SELENA-SLEDAI (SS) 6 on stable routine SLE therapy for 30d received belimumab 1 or 10 mg/kg, or placebo, plus routine therapy, for 52/76wks. Efficacy analyses: SS, BILAG, and SS Flare Index (SFI). Primary endpoint: SLE Responder Index (SRI)-improvement in SS (4-point decrease), no new BILAG A and no more than 1 B flare, and no worsening in PGA (<0.3-point increase) vs baseline at wk52. Results: Mean baseline characteristics were similar across treatment groups. SRI response rates: 46.2% (p¼0.006) and 50.6% (p<0.0001) with belimumab 1 and 10 mg/ kg, respectively, vs 38.8% with placebo. Significant improvements were seen with belimumab 10 mg/kg vs placebo for SRI at wk52, SS 4-point reduction, mean % PGA reduction at wk24, reduction in corticosteroid use, and no new BILAG 1A/2B flares. Statistically significant improvement was seen in 1 belimumab treatment group vs placebo for time to SRI response and mean response duration. Significantly greater reductions in IgG and anti-dsDNA and increases in complement values from baseline occurred with belimumab (both doses) vs placebo. Conclusion: In this pooled analysis, belimumab significantly reduced SLE disease activity and flare rates, reduced corticosteroid use, and reduced autoantibody and increased complement values in seropositive SLE patients.
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Protein synthesis of the pro-inflammatory protein S100A8/A9 in plasmacytoid dendritic cells and altered cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic inflammation in many different organ systems, activation of leukocytes and production of pro-inflammatory cytokines. The heterodimer of the cytosolic calciumbinding proteins S100A8 and S100A9 (S100A8/A9) is secreted by activated polymorphonuclear cells (PMNs) and monocytes and serves as a serum marker for several inflammatory diseases. Furthermore, S100A8 and S100A9 have many pro-inflammatory properties such as binding to the Toll like receptor 4 (TLR4). Aim: In this study we investigated if plasmacytoid dendritic cells (pDCs) could synthesize S100A8/A9 and if aberrant cell surface S100A8/A9 could be seen in SLE. Patients and Methods: Flow cytometry, confocal microscopy and real-time PCR of flow cytometry-sorted cells were used to measure cell surface S100A8/A9, intracellular S100A8/A9 and mRNA levels of S100A8 and S100A9, respectively. Patients were recruited from an ongoing prospective study of SLE. Results: Cell surface S100A8/A9 was detected on all leukocyte subpopulations investigated except for T cells. By confocal microscopy, real-time PCR and stimulation assays we could demonstrate that pDCs, monocytes and PMNs could synthesize S100A8/A9 and levels of cell surface S100A8/A9 were associated with disease activity.
Upon immune complex activation, pDCs up-regulated the cell surface S100A8/A9. SLE patients had also increased serum levels of S100A8/A9. Conclusions: Patients with SLE had increased cell surface S100A8/A9 which could be important in amplification and persistence of inflammation. Importantly, pDCs were able to synthesize S100A8/ A9 proteins and up-regulate the cell surface expression upon immune complex-stimulation. Thus, S100A8/A9 may be a potent target for treatment of inflammatory diseases such as SLE.
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Excessive "4baff (an alternate-splice isoform that acts as a transcription factor) enhances BAFF production in systemic lupus erythematosus Pers JO, Tobo´n GJ, Le Pottier L, Youinou P, Jamin C Brest University Medical School Hospital, Immunology, Brest, France Introduction: Elevated expression of BAFF contributes to the expansion of self-reactive B cells during the establishment of tolerance. Mechanisms leading to BAFF over-expression in autoimmune settings, such as SLE or primary Sjo¨gren's syndrome (SS) are not understood. Three transcriptional variants of the BAFF gene have been described, including a truncated Á3BAFF form that inhibits BAFF, by forming non-functional heterotrimers with full-length (FL) BAFF. Aim: To report the discovery and the role of a new transcript for BAFF. Patients and Methods: A 3' RACE-PCR was performed in SS B cells. To assess the biochemical properties of the new variant, RAMOS B cells were transfected with pIRES2-EGFP-Á4BAFF. A ChIP analysis and an EMSA using a digoxigenin-labeled consensus NFkB binding probe were performed to evaluate whether Á4BAFF might function as a transcriptional regulator of BAFF. Results: Another transcript with deletion of nucleotides 749 to 861 encoding the predicted exon 4 was revealed. A new in-frame stop codon was generated resulting in a truncated protein. In transfected RAMOS B cells, two bands at 21 and 17-kD prove to belong to Á4BAFF, which is very telling of a post-translational modification. PNGase-F treatment showed that Á4BAFF was glycosylated. Á4BAFF was located in the nucleus and, contrary to FL-BAFF, absent from the cytoplasm. The Á4BAFF protein bound to the BAFF promoter and activates its own gene to increase BAFF production. A protein/DNA complex with a supershift was detected in ChIP when the anti-BAFF mAb was added. The Á4BAFF protein was found in B cells from patients with SLE or in epithelial cells from patients with SS. Conclusion: We expand the view of BAFF gene regulation, which contribute a better understanding of physiological mechanisms of B cell survival, and of pathophysiology of autoreactive B cells. Our work introduces an entirely novel concept in biology suggesting that a human cytokine gene can be transcriptionally regulated by the activity of one of its own splice variants. Introduction: Systemic Lupus Erythematosus (SLE) has long been associated with Epstein-Barr Virus (EBV) infection, however the mechanisms linking EBV to SLE immunopathology have remained elusive. The association relies on increased anti-EBV antibody levels and more frequent detection of EBV DNA in SLE patients compared to healthy controls. Also, cross-reactivity of autoimmune antibodies between nuclear self-antigens and EBV proteins has been described. Aim: Here we investigate if frequent EBV replication in a large cohort of SLE patients is associated with dysfunctional anti-EBV CD8 þ T cell responses. Patients and Methods: We recruited 32 age-and sexmatched healthy controls and 99 SLE patients divided in 69 inactive patients (SLEDAI 6) and 30 active patients (SLEDAI > 6). CD8 þ T cells specific for EBV were detected with peptide-MHC tetramer complexes and their functionality was measured post peptide stimulation by intracellular staining with anti-cytokine and anti-chemokine as well as anti-Granzyme B antibodies. Results: In SLE patients, significantly elevated EBV viral loads are associated with impaired EBV-specific CD8 þ T cell cytokine responses (IFN-g: P¼0.006, TNF-a: P¼0.006, IL-2: P¼0.001, n¼36) and cytotoxicity (CD107a: P¼0.001, Granzyme B: P¼0.004), compared to healthy controls. Importantly, the functional defects observed were EBV-restricted as CMV-specific responses were not found significantly altered in SLE patients.
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Moreover, we demonstrate that EBV-specific CD8 þ T cell dysfunctionality is a consequence of their Programmed Death 1 (PD-1) receptor up-regulation, as blocking this pathway reverses the dysfunctional phenotype. Finally, prospective monitoring of lupus patients revealed that disease flares precede EBV reactivation. Conclusion: After four decades of dispute regarding the role of EBV in SLE, we finally conclude that EBV-specific CD8 þ T cell responses in SLE patients are functionally impaired, and that EBV reactivation is rather an aggravating consequence than a cause of SLE immunopathology. We therefore propose that autoimmune B cell activation during flares drives frequent EBV reactivation, which contributes in a vicious circle to the perpetuation of immune activation in SLE patients. Our results also imply that immunological interventions aimed at restoring anti-EBV cytotoxic responses might be beneficial to SLE patients.
